(Q38066566)

28 August 2017

1 reference

title

Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. (English)

1 reference

28 August 2017

David G Parkes

1

1 reference

28 August 2017

Kenneth F Mace

series ordinal

2

1 reference

28 August 2017

Michael E Trautmann

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

12 December 2012

1 reference

Expert Opinion on Drug Discovery

28 August 2017

published in

1 reference

28 August 2017

volume

8

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

219-244

1 reference

Standards of medical care in diabetes--2012

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Fatty liver: a novel component of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

A role for glucagon-like peptide-1 in the central regulation of feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

The incretin system and its role in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Physiology of GLP-1--lessons from glucoincretin receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Therapeutic approaches to preserve islet mass in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Mouse pancreatic beta-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Bioactive peptides from lizard venoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Relationships of upper gastrointestinal motor and sensory function with glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Regulation of glucose transporters and hexose uptake in 3T3-L1 adipocytes: glucagon-like peptide-1 and insulin interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Exenatide improves hypertension in a rat model of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Investigation of exenatide elimination and its in vivo and in vitro degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Effect of renal impairment on the pharmacokinetics of exenatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Liraglutide as additional treatment for type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Association of pancreatitis with glucagon-like peptide-1 agonist use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

A cohort study of acute pancreatitis in relation to exenatide use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Exendin-4 and exendin-(9–39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7–36)NH2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.741580

10.1517/17460441.2013.741580

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference